Cargando…

Effective Inhibition of MYC-Amplified Group 3 Medulloblastoma Through Targeting EIF4A1

PURPOSE: In medulloblastoma (MB), group 3 (G3) patients with MYC amplification tend to exhibit worse prognosis, thus creating a need for novel effective therapies. As the driver and crucial dependency for MYC-amplified G3-MB, MYC has been proven to be a prospective therapeutic target. Here, we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yang, Li, Tiantian, Tian, Shuaiwei, Meng, Wei, Sui, Yi, Yang, Jian, Wang, Baocheng, Liang, Zhuangzhuang, Zhao, Heng, Han, Yipeng, Tang, Yujie, Zhang, Lei, Ma, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721120/ https://www.ncbi.nlm.nih.gov/pubmed/33299354 http://dx.doi.org/10.2147/CMAR.S278844

Ejemplares similares

Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
por: Wang, Jiajia, et al.
Publicado: (2020)

Systematic analysis of MCM3 in pediatric medulloblastoma via multi-omics analysis
por: Cao, Liangliang, et al.
Publicado: (2022)

Corrigendum: Systematic analysis of MCM3 in pediatric medulloblastoma via multi-omics analysis
por: Cao, Liangliang, et al.
Publicado: (2022)

MEDB-05. Survival and prognostic factors in childhood medulloblastoma: A China single center experience from 2006 to 2015
por: Liang, zhuangzhuang, et al.
Publicado: (2022)

MBRS-62. CURAXIN CBL0137 INHIBITS THE VIABILITY OF CANCEROUS CELLS IN PRE-CLINIC MODELS OF MYC-AMPLIFIED MEDULLOBLASTOMA
por: Wang, Jiajia, et al.
Publicado: (2020)

Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
por: Ecker, Jonas, et al.
Publicado: (2015)

Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma
por: Bharambe, Harish Shrikrishna, et al.
Publicado: (2020)

MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA
por: Kameda-Smith, Michelle, et al.
Publicado: (2020)

Proof-of-Concept for Liquid Biopsy Disease Monitoring of MYC-Amplified Group 3 Medulloblastoma by Droplet Digital PCR
por: Stepien, Natalia, et al.
Publicado: (2023)

BIOL-10. DISTRIBUTION AND VULNERABILITY OF TRANSCRIPTIONAL OUTPUTS ACROSS THE GENOME IN MYC-AMPLIFIED MEDULLOBLASTOMA CELLS
por: Yang, Rui, et al.
Publicado: (2021)

MEDB-79. MYC-driven upregulation of thede novo serine and glycine pathway is a novel therapeutic target for Group 3 MYC-amplified Medulloblastoma
por: Adiamah, Magretta, et al.
Publicado: (2022)

MEDB-36. Clinical and molecular heterogeneity withinMYC andMYCN amplified medulloblastoma
por: Schwalbe, Edward, et al.
Publicado: (2022)

An Integrated Analysis of Tumor Purity of Common Central Nervous System Tumors in Children Based on Machine Learning Methods
por: Yang, Jian, et al.
Publicado: (2021)

Cytotoxic effects and tolerability of gemcitabine and axitinib in a xenograft model for c-myc amplified medulloblastoma
por: Schwinn, Stefanie, et al.
Publicado: (2021)

CircPIK3C2A Facilitates the Progression of Glioblastoma via Targeting miR-877-5p/FOXM1 Axis
por: Yang, Jian, et al.
Publicado: (2021)

EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA
por: Valinciute, Gintvile, et al.
Publicado: (2021)

MEDB-81. Combined inhibition of CDK11 and EZH2 results in regression of MYC-amplified medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
por: Vollmer, Johanna, et al.
Publicado: (2023)

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
por: Valinciute, Gintvile, et al.
Publicado: (2023)

Polymorphisms of insulin receptor substrate 2 are putative biomarkers for pediatric medulloblastoma: considering the genetic susceptibility and pathological diagnoses
por: Baocheng, Wang, et al.
Publicado: (2017)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

EMBR-02. OLIG2 REPRESENTS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN MYC-AMPLIFIED MEDULLOBLASTOMA RELAPSE AND METASTASIS
por: Xu, Zhenhua, et al.
Publicado: (2021)

Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma
por: Kameda-Smith, Michelle M., et al.
Publicado: (2022)

EMBR-07. MYC BUT NOT MYCN GENERATES AGGRESSIVE GROUP 3 MEDULLOBLASTOMA BY ARF PATHWAY SUPPRESSION
por: Mainwaring, Oliver, et al.
Publicado: (2021)

Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma
por: Chaturvedi, Nagendra K., et al.
Publicado: (2019)

The tentative application of en bloc concept in the pediatric brain tumor: Experience from a large pediatric center in china
por: Cao, Liangliang, et al.
Publicado: (2022)

Comprehensive Metabolic Profiling of MYC-Amplified Medulloblastoma Tumors Reveals Key Dependencies on Amino Acid, Tricarboxylic Acid and Hexosamine Pathways
por: Pham, Khoa, et al.
Publicado: (2022)

SURG-04. THE APPLICATION OF EN BLOC RESECTION IN THE OPERATION OF PEDIATRIC POSTERIOR FOSSA TUMOR
por: Jie, Ma, et al.
Publicado: (2020)

MBRS-57. IDENTIFICATION OF MYC-DEPENDENT THERAPEUTIC VULNERABILITIES FOR TARGETING GROUP 3 MEDULLOBLASTOMA
por: Llargués-Sistac, Gemma, et al.
Publicado: (2020)

Author Correction: Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma
por: Kameda-Smith, Michelle M., et al.
Publicado: (2023)

Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma
por: Li, Meng, et al.
Publicado: (2022)

Identification and Functional Characterization of Novel MYC-Regulated Long Noncoding RNAs in Group 3 Medulloblastoma
por: Rea, Jessica, et al.
Publicado: (2021)

MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS
por: Vollmer, Johanna, et al.
Publicado: (2020)

N-myc gene expression and oncoprotein characterisation in medulloblastoma.
por: Garson, J. A., et al.
Publicado: (1989)

Mouse medulloblastoma driven by CRISPR activation of cellular Myc
por: Vo, BaoHan T., et al.
Publicado: (2018)

OMIC-03. TRANSLATIONAL CONTROL IN MYC AND MYCN MEDULLOBLASTOMA
por: Schmidt, Christin, et al.
Publicado: (2021)

Targeting protein folding in N‐Myc‐driven medulloblastoma
por: Valinciute, Gintvile, et al.
Publicado: (2023)

Oncogenic MYC amplifies mitotic perturbations
por: Littler, Samantha, et al.
Publicado: (2019)

SURG-01. The Tentative Application of En Bloc concept in the Pediatric Brain Tumor: A Retrospective Study of 171 Cases from A Large Pediatric Center in China
por: Cao, Liangliang, et al.
Publicado: (2022)

c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients
por: von Bueren, André O, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ho8v7n4pb8gtq2abj1tok19tth